Navigation Links
Kendle Appoints Jeffrey M. Zucker to Lead Global Patient Recruitment Efforts
Date:8/23/2010

CINCINNATI, Aug. 23 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the appointment of Jeffrey M. Zucker as Senior Director and Global Head, Patient Recruitment.  Zucker will provide global leadership for the development and implementation of innovative strategies to accelerate patient recruitment, improve retention and support the timely and efficient delivery of Phase I-IV clinical development programs for the Company's biopharmaceutical customers.  He brings nearly 15 years of clinical development and management experience to Kendle.

"Patient recruitment is at the core of the clinical development process," said Stephen Cutler, PhD, Senior Vice President and Chief Operating Officer.  "Finding the right patients for the right studies and keeping them engaged throughout is essential to producing sound clinical research.  Jeff's extensive management experience across many facets of the biopharmaceutical industry will be a great asset for our customers and we are pleased to welcome him to Kendle."

Zucker brings extensive experience from across the biopharmaceutical industry, including management positions focused on site selection and patient recruitment.  In his most recent position, he led global trial optimization efforts for Merck & Co. He also has served as Director of Inpatient Operations at CRI Worldwide and as founder and President of Applied Research Trials, a biopharmaceutical consulting firm focused on improving clinical research trials and processes.  Zucker has held leadership positions for Eli Lilly, Princeton Biomedical Research and multiple clinical investigative sites. He holds a Master of Science in Group Process and Group Psychotherapy from Hahnemann University in Philadelphia and a Bachelor of Science in psychology from Pennsylvania State University.  

Innovative patient recruitment strategies in support of investigative sites have earned Kendle consistent recognition as a CRO of choice.  The Company is the only CRO to be ranked consistently among the top three CROs to work with in the 2010, 2009, 2008 and 2007 CenterWatch surveys of U.S. and European investigative sites.  

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's website at www.kendle.com.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle Rated a Top CRO to Work with for Fourth Consecutive Year
2. Kendle Announces New Revolving Credit Facility
3. Kendle Announces Details Regarding Fourth Quarter and Full-Year 2009 Earnings Conference Call and Webcast
4. Kendle to Present at UBS Global Life Sciences Conference
5. Kendle to Present at Robert Baird 2009 Health Care Conference
6. Kendle Realigns C-Suite Leadership to Drive Increased Innovation, Productivity and Organizational Efficiency
7. Kendle Appoints Stephen Cutler, PhD Senior Vice President and Chief Operating Officer
8. Kendle Names Jarrod Pontius Chief Legal Officer
9. Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila
10. Kendle Announces First Quarter 2009 Results
11. Kendle Announces Departure of Senior Vice President and CFO Karl Buzz Brenkert III; Appoints Keith A. Cheesman as Successor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 ... ... announces publication of a United States multicenter, prospective clinical study that demonstrates ... point-of-care diagnostic test capable of identifying clinically significant acute bacterial and viral ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
Breaking Biology Technology:
(Date:5/23/2017)... GENOA, Italy , May 23, 2017  Hunova, the first robotic ... and trunk, has been officially launched in Genoa, Italy ... Europe and the USA . The ... launched on the market by the IIT spin-off Movendo Technology thanks to ... view the Multimedia News Release, please click: ...
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
(Date:4/11/2017)... BEACH GARDENS, Fla. , April 11, 2017 ... identity management and secure authentication solutions, today announced ... contract by Intelligence Advanced Research Projects Activity (IARPA) ... for IARPA,s Thor program. "Innovation has ... onset and IARPA,s Thor program will allow us ...
Breaking Biology News(10 mins):